Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Journal of Virological Methods
Susan WitkoChristopher L Parks

Abstract

Propagation-defective vesicular stomatitis virus (VSV) vectors that encode a truncated G protein (VSV-Gstem) or lack the G gene entirely (VSV-DeltaG) are attractive vaccine vectors because they are immunogenic, cannot replicate and spread after vaccination, and do not express many of the epitopes that elicit neutralizing anti-VSV immunity. To consider advancing non-propagating VSV vectors towards clinical assessment, scalable technology that is compliant with human vaccine manufacturing must be developed to produce clinical trial material. Accordingly, two propagation methods were developed for VSV-Gstem and VSV-DeltaG vectors encoding HIV gag that have the potential to support large-scale production. One method is based on transient expression of G protein after electroporating plasmid DNA into Vero cells and the second is based on a stable Vero cell line that contains a G gene controlled by a heat shock-inducible transcription unit. Both methods reproducibly supported production of 1 x 10(7) to 1 x 10(8) infectious units (I.U.s) of vaccine vector per milliliter. Results from these studies also showed that optimization of the G gene is necessary for abundant G protein expression from electroporated plasmid DNA or from DNA inte...Continue Reading

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Gossen, H Bujard
Jan 1, 1987·Molecular and Cellular Biology·R B DuBridgeM P Calos
Aug 29, 1995·Proceedings of the National Academy of Sciences of the United States of America·S P WhelanG T Wertz
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·N D LawsonJ K Rose
Apr 1, 1995·Molecular and Cellular Biology·A M ZubiagaM E Greenberg
Jun 1, 1994·Biologicals : Journal of the International Association of Biological Standardization·S Y Chan
Nov 1, 1994·Molecular and Cellular Biology·P E Kroeger, R I Morimoto
Jan 1, 1995·Annual Review of Cell and Developmental Biology·C Wu
Jan 1, 1996·Intervirology·J L Meier, M F Stinski
Oct 1, 1997·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·M G ReeseD Haussler
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·A TakadaY Kawaoka
Mar 14, 1998·Journal of Virology·P SpielhoferH Y Naim
May 23, 1998·Human Molecular Genetics·M Q Zhang
Apr 10, 1999·Journal of Virology·A RobertsJ K Rose
Dec 3, 2002·Current Opinion in Biotechnology·Stéphane Y Corbel, Fabio M V Rossi
Mar 1, 2003·Journal of Virology·Emmanuelle BlanchardPhilippe Roingeard
Jul 10, 2003·Cytotherapy·J C FratantoniL N Liu
Nov 30, 2004·Virus Research·Himangi R JayakarMichael A Whitt
Jan 15, 2005·Methods : a Companion to Methods in Enzymology·Claire RomeChrit T W Moonen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.